Cabotegravir/rilpivirine

Cabotegravir/rilpivirine
Combination of
CabotegravirIntegrase strand transfer inhibitor (INSTI)
RilpivirineNon-nucleoside reverse transcriptase inhibitor (NNRTI)
Clinical data
Trade namesCabenuva, Vocabria, Rekambys
AHFS/Drugs.comMultum Consumer Information
MedlinePlusa621009
License data
Pregnancy
category
  • AU: B1
Routes of
administration		Intramuscular
ATC code
  • None
Legal status
Legal status
Identifiers
KEGG

Cabotegravir/rilpivirine, sold under the brand name Cabenuva, is a co-packaged antiretroviral medication for the treatment of HIV/AIDS.[3][4][5][6][7] It contains cabotegravir and rilpivirine in a package with two separate injection vials.[3][4][6]

The most common adverse reactions include injection site reactions, fever or feeling hot (pyrexia), fatigue, headache, musculoskeletal pain, nausea, sleep disorders, dizziness and rash.[3][4][8]

The co-packaged medication was approved for medical use in the United States in January 2021.[4][8][9] It is the first FDA-approved injectable, complete regimen for HIV-infected adults that is administered once a month.[4][5] It is also approved for use in Canada.[1] In the European Union, the two medications are approved separately and have different brand names: Vocabria (for cabotegravir) and Rekambys (for rilpivirine).[10][11][12]

  1. ^ a b "Cabenuva Product information". Health Canada. 25 April 2012. Retrieved 22 January 2021.
  2. ^ "Summary Basis of Decision (SBD) for Vocabria/Cabenuva". Health Canada. 23 October 2014. Retrieved 29 May 2022.
  3. ^ a b c d "Cabenuva- cabotegravir and rilpivirine kit". DailyMed. Retrieved 13 February 2021.
  4. ^ a b c d e f "FDA Approves First Extended-Release, Injectable Drug Regimen for Adults Living with HIV". U.S. Food and Drug Administration (FDA) (Press release). 21 January 2021. Retrieved 21 January 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  5. ^ a b c "Cabenuva and Vocabria approved for HIV infection". U.S. Food and Drug Administration (FDA). 27 January 2021. Retrieved 27 January 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  6. ^ a b "ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment". ViiV Healthcare. 21 January 2021. Retrieved 21 January 2021 – via Business Wire.
  7. ^ Howe ZW, Norman S, Lueken AF, Huesgen E, Farmer EK, Jarrell K, et al. (August 2021). "Therapeutic review of cabotegravir/rilpivirine long-acting antiretroviral injectable and implementation considerations at an HIV specialty clinic". Pharmacotherapy. 41 (8): 686–699. doi:10.1002/phar.2605. PMID 34130357. S2CID 235451020.
  8. ^ a b "Drug Trials Snapshot: Cabenuva". U.S. Food and Drug Administration (FDA). 20 January 2021. Retrieved 17 February 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  9. ^ "Drug Approval Package: Cabotegravir". U.S. Food and Drug Administration (FDA). 3 March 2021. Retrieved 14 September 2021.
  10. ^ "Janssen Announces European Commission Authorisation of the First Complete Long-Acting Injectable HIV Treatment in Europe" (Press release). Janssen. Retrieved 22 January 2021 – via Business Wire.
  11. ^ "Rekambys EPAR". European Medicines Agency (EMA). 13 October 2020. Retrieved 4 January 2021.
  12. ^ Cite error: The named reference Vocabria EPAR was invoked but never defined (see the help page).